{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:57:16Z","timestamp":1791280636233,"version":"4.1.0"},"reference-count":108,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T00:00:00Z","timestamp":1490745600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2017,3,29]],"date-time":"2017-03-29T00:00:00Z","timestamp":1490745600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2017,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    New all\u2010oral direct\u2010acting antivirals (\n                    <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>\n                    ) have changed the hepatitis C virus (\n                    <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                    ) treatment landscape. Given that dermatologists frequently encounter\n                    <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                    \u2010infected patients, knowledge of the current treatment options and their utility in treating\n                    <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                    \u2010associated dermatologic disorders is important. In addition to highlighting the new treatment options, we review four classically\n                    <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                    \u2010associated dermatologic disorders \u2013 mixed cryoglobulinaemia (\n                    <jats:styled-content style=\"fixed-case\">MC<\/jats:styled-content>\n                    ), lichen planus (\n                    <jats:styled-content style=\"fixed-case\">LP<\/jats:styled-content>\n                    ), porphyria cutanea tarda (\n                    <jats:styled-content style=\"fixed-case\">PCT<\/jats:styled-content>\n                    ) and necrolytic acral erythema (\n                    <jats:styled-content style=\"fixed-case\">NAE<\/jats:styled-content>\n                    ) \u2013 and examine the role for all\u2010oral direct\u2010acting antiviral (\n                    <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>\n                    ) regimens in their treatment. A literature search of English\u2010language publications was conducted of the PubMed and\n                    <jats:styled-content style=\"fixed-case\">EMBASE<\/jats:styled-content>\n                    databases using search terms including \u2018hepatitis C\u2019, \u2018direct acting antivirals\u2019, \u2018cutaneous\u2019, \u2018mixed cryoglobulinemia\u2019, \u2018necrolytic acral erythema\u2019, \u2018lichen planus\u2019, \u2018porphyria cutanea tarda\u2019, \u2018rash\u2019, as well as specific drug names, related terms and abbreviations. Currently, limited data exist on the use of\n                    <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>\n                    s in\n                    <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                    \u2010infected patients with cutaneous side\u2010effects, although treatment of the underlying\n                    <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                    is now recommended for nearly all patients, with the new drugs offering much\u2010improved dosage schedules and side\u2010effect profiles. The most data exist for\n                    <jats:styled-content style=\"fixed-case\">MC<\/jats:styled-content>\n                    , in which several studies suggest that\n                    <jats:styled-content style=\"fixed-case\">DAA<\/jats:styled-content>\n                    s and achievement of sustained virologic response (\n                    <jats:styled-content style=\"fixed-case\">SVR<\/jats:styled-content>\n                    ) improve cutaneous symptoms. Studies of both older and newer regimens are limited by their small size, retrospective nature, lack of appropriate controls and wide variability in study protocols. Given the strong association, screening for\n                    <jats:styled-content style=\"fixed-case\">HCV<\/jats:styled-content>\n                    should be considered in patients with\n                    <jats:styled-content style=\"fixed-case\">MC<\/jats:styled-content>\n                    ,\n                    <jats:styled-content style=\"fixed-case\">LP<\/jats:styled-content>\n                    ,\n                    <jats:styled-content style=\"fixed-case\">PCT<\/jats:styled-content>\n                    and\n                    <jats:styled-content style=\"fixed-case\">NAE<\/jats:styled-content>\n                    .\n                  <\/jats:p>","DOI":"10.1111\/jdv.14186","type":"journal-article","created":{"date-parts":[[2017,3,2]],"date-time":"2017-03-02T10:28:44Z","timestamp":1488450524000},"page":"1260-1270","source":"Crossref","is-referenced-by-count":25,"title":["Hepatitis C virus and its cutaneous manifestations: treatment in the direct\u2010acting antiviral era"],"prefix":"10.1111","volume":"31","author":[{"given":"L.E.","family":"Wiznia","sequence":"first","affiliation":[{"name":"Ronald O. Perelman Department of Dermatology New York University School of Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.E.","family":"Laird","sequence":"additional","affiliation":[{"name":"Ronald O. Perelman Department of Dermatology New York University School of Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr","given":"A.G.","family":"Franks","sequence":"additional","affiliation":[{"name":"Ronald O. Perelman Department of Dermatology New York University School of Medicine New York NY USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,3,29]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27950"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/M13-1133"},{"key":"e_1_2_9_4_1","unstructured":"Recommendations for testing managing and treating hepatitis C. URLhttp:\/\/www.hcvguidelines.org. (last accessed: January 12 2017)."},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199910)42:10<2204::AID-ANR24>3.0.CO;2-D"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-015-9684-3"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2010.07.009"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/jvh.12074"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-158-5-201303050-00005"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2012.144878"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-10-200711200-00003"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.20119"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2006.099150"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1478-3231.2009.02156.x"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21927"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2006.06.010"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2011.08.006"},{"key":"e_1_2_9_18_1","first-page":"835","article-title":"Diagnosis and management of hepatitis C","volume":"91","author":"Wilkins T","year":"2015","journal-title":"Am Fam Physician"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.24554"},{"key":"e_1_2_9_20_1","unstructured":"Incivek (telaprevir)[package insert].Cambridge MA:Vertex Pharmaceuticals Inc."},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1177\/1060028014539274"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1177\/1203475415595775"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2015.03.025"},{"key":"e_1_2_9_24_1","first-page":"127","article-title":"Dermatologic extrahepatic manifestations of hepatitis C","volume":"3","author":"Dedania B","year":"2015","journal-title":"J Clin Transl Hepatol"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-123-8-199510150-00008"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-007-8070-x"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1208642"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2003.10.001"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.27623"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(96)80200-5"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/0961203314556140"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2015-208339"},{"key":"e_1_2_9_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22168"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.23305"},{"key":"e_1_2_9_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2014.05.017"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.meg.0000108342.41221.0c"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-4453(98)80022-4"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02358379"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.23562"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28297"},{"key":"e_1_2_9_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(16)01520-8"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28753"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew268"},{"key":"e_1_2_9_44_1","doi-asserted-by":"crossref","first-page":"S897","DOI":"10.14309\/00000434-201510001-02154","article-title":"Virological efficacy of new, oral, direct\u2010acting antivirals in hepatitis C patients with mixed cryoglobulinemia","volume":"110","author":"Mittal R","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_9_45_1","first-page":"1","article-title":"Virological and clinical response to interferon\u2010free regimens in patients with HCV\u2010related mixed cryoglobulinemia: preliminary results of a prospective pilot study","volume":"17","author":"Gragnani L","year":"2016","journal-title":"Curr Drug Targets"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2015.04.002"},{"key":"e_1_2_9_47_1","doi-asserted-by":"publisher","DOI":"10.12890\/2015_000299"},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcv.2015.09.003"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr\u20102016\u2010215293"},{"key":"e_1_2_9_50_1","first-page":"1","article-title":"Successful ledipasvir + sofosbuvir treatment of active synovitis in a rheumatoid arthritis patient with hepatitis C virus\u2010related mixed cryoglobulinemia","author":"Koga T","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"1","key":"e_1_2_9_51_1","first-page":"956A","article-title":"Virological response to ombitasvir\/paritaprevir\/ritonavir+ dasabuvir+ribavirin in 150 patients with mixed cryoglobulinaemia and HCV infection","volume":"63","author":"Gheorghe L","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1080\/00325481.2015.1021660"},{"key":"e_1_2_9_53_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2014-206180"},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMcp1103641"},{"key":"e_1_2_9_55_1","volume-title":"Dermatology","author":"Bolognia J","year":"2012"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1601-0825.2010.01670.x"},{"key":"e_1_2_9_57_1","doi-asserted-by":"publisher","DOI":"10.1001\/archdermatol.2009.200"},{"key":"e_1_2_9_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70025-3"},{"key":"e_1_2_9_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.dld.2006.06.008"},{"key":"e_1_2_9_60_1","doi-asserted-by":"publisher","DOI":"10.1159\/000450679"},{"key":"e_1_2_9_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/ctg.2016.37"},{"key":"e_1_2_9_62_1","doi-asserted-by":"publisher","DOI":"10.1111\/cup.12656"},{"key":"e_1_2_9_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(03)00346-5"},{"key":"e_1_2_9_64_1","doi-asserted-by":"publisher","DOI":"10.1080\/00365520310000672a"},{"key":"e_1_2_9_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0190-9622(99)70402-0"},{"key":"e_1_2_9_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510270627"},{"key":"e_1_2_9_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/0168-8278(95)80438-2"},{"key":"e_1_2_9_68_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1018854906444"},{"key":"e_1_2_9_69_1","first-page":"525","article-title":"Interferon treatment of porphyria cutanea tarda associated with chronic hepatitis type C","volume":"44","author":"Okano J","year":"1997","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_9_70_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1026681218915"},{"key":"e_1_2_9_71_1","first-page":"1020","article-title":"Porphyrie cutan\u00e9e tardive familiale r\u00e9v\u00e9l\u00e9e par une h\u00e9patite C chronique. \u00c0 propos d'un cas. La Revue de M\u00e9decine","volume":"17","author":"About I","year":"1996","journal-title":"Interne"},{"key":"e_1_2_9_72_1","doi-asserted-by":"publisher","DOI":"10.1007\/PL00009978"},{"key":"e_1_2_9_73_1","first-page":"345","article-title":"Chronic hepatitis C associated with porphyria cutanea tarda","volume":"91","author":"Dohmen K","year":"1994","journal-title":"Nihon Shokakibyo Gakkai Zasshi"},{"key":"e_1_2_9_74_1","first-page":"1148","article-title":"Porphyria cutanea tarda and chronic hepatitis C. Course after interferon therapy","volume":"18","author":"Grasset D","year":"1994","journal-title":"Gastroenterol Clin Biol"},{"key":"e_1_2_9_75_1","doi-asserted-by":"publisher","DOI":"10.1159\/000045980"},{"key":"e_1_2_9_76_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.5913"},{"key":"e_1_2_9_77_1","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.35072"},{"key":"e_1_2_9_78_1","first-page":"38","article-title":"Development of porphyria cutanea tarda in a chronic hepatitis C patient with indetectable viremia under treatment with peg\u2010interferon plus ribavirin","volume":"36","author":"Frider B","year":"2006","journal-title":"Acta Gastroenterol Latinoam"},{"key":"e_1_2_9_79_1","first-page":"302","article-title":"Porphyria cutanea tarda, dermatomyositis and non\u2010Hodgkin lymphoma in virus C infection","volume":"13","author":"Bauza A","year":"2003","journal-title":"Eur J Dermatol"},{"key":"e_1_2_9_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2004.10.029"},{"key":"e_1_2_9_81_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9945-7"},{"key":"e_1_2_9_82_1","first-page":"160","article-title":"Hepatitis C & porphyria cutanea tarda experience in 2 tertiary centres","volume":"28","author":"Hennessy T","year":"2013","journal-title":"J Gastroenterol Hepatol"},{"key":"e_1_2_9_83_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.13936"},{"key":"e_1_2_9_84_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2016.3036"},{"issue":"1","key":"e_1_2_9_85_1","first-page":"960A","article-title":"Interferon, ribavirin or direct antiviral agent\u2010based regimens for treatment of hepatitis C among patient with porphyria cutanea tarda","volume":"63","author":"Singal A","year":"2016","journal-title":"Hepatology"},{"key":"e_1_2_9_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(01)00160-X"},{"key":"e_1_2_9_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-4362.1996.tb02997.x"},{"key":"e_1_2_9_88_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2005.04.049"},{"key":"e_1_2_9_89_1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.136.6.755"},{"key":"e_1_2_9_90_1","first-page":"20709","article-title":"Necrolytic acral erythema","volume":"19","author":"Yost JM","year":"2013","journal-title":"Dermatol Online J"},{"key":"e_1_2_9_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2008.08.046"},{"key":"e_1_2_9_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2011.11.963"},{"key":"e_1_2_9_93_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2006.04316.x"},{"key":"e_1_2_9_94_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2003.09.017"},{"key":"e_1_2_9_95_1","first-page":"016","article-title":"Successful treatment of necrolytic acral erythema with ledipasvir and sofosbuvir","volume":"3","author":"Shaikh GFR","year":"2015","journal-title":"J Clin Dermatol There"},{"key":"e_1_2_9_96_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12485"},{"key":"e_1_2_9_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature04077"},{"key":"e_1_2_9_98_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.R110.133017"},{"key":"e_1_2_9_99_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2009.07.005"},{"key":"e_1_2_9_100_1","doi-asserted-by":"publisher","DOI":"10.3390\/v7122968"},{"key":"e_1_2_9_101_1","unstructured":"Daklinza(daclatasvir) [package insert].Princeton NJ:Bristol\u2010Myers Squibb Company."},{"key":"e_1_2_9_102_1","unstructured":"Zepatier(elbasvir and grazoprevir) [package insert].Whitehouse Station NJ:Merck & Co. Inc."},{"key":"e_1_2_9_103_1","unstructured":"Harvoni(ledipasvir and sofosbuvir) [package insert].Foster City CA:Gilead Sciences Inc."},{"key":"e_1_2_9_104_1","unstructured":"Technivie(ombitasvir paritaprevir and ritonavir) [package insert].North Chicago IL:AbbVie Inc."},{"key":"e_1_2_9_105_1","unstructured":"Viekira Pak(ombitasvir paritaprevir and ritonavir tablets; dasabuvir tablets) [package insert].North Chicago IL:AbbVie Inc."},{"key":"e_1_2_9_106_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28467"},{"key":"e_1_2_9_107_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61036-9"},{"key":"e_1_2_9_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28422"},{"key":"e_1_2_9_109_1","unstructured":"Epclusa(sofosbuvir and velpatasvir) [package insert].Foster City CA:Gilead Sciences Inc."}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fjdv.14186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14186","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.14186","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.14186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:39:13Z","timestamp":1791279553000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.14186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,29]]},"references-count":108,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["10.1111\/jdv.14186"],"URL":"https:\/\/doi.org\/10.1111\/jdv.14186","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,3,29]]}}}